Tag:
Janssen Biotech
Latest Headlines
Latest Headlines
J&J releases more Doxil to the market
Johnson & Johnson and the FDA sprang into action in 2011 when J&J's popular chemo drug Doxil became hard to get because of problems with the contract manufacturer. But it also figured out a process by which it could have it manufactured at one plant and finished at another.
J&J fights $327M Risperdal verdict, saying no one was harmed
South Carolina Circuit Judge Roger Couch took a particularly creative approach when he levied a $327 million penalty against Johnson & Johnson in the state's Risperdal case.
Zytiga data presents new threat to Provenge
Johnson & Johnson's ( $JNJ ) prostate cancer pill Zytiga has shown it's effective in patients who haven't yet received chemotherapy.
UPDATED: J&J said to settle TX Risperdal case for $158M
Johnson & Johnson ( $JNJ ) says it will pay $158 million to settle a high-profile Texas suit alleging that it defrauded the state by misleading doctors about its antipsychotic drug Risperdal .
Witness: J&J memo urged off-label Risperdal push
Texas officials unveiled an internal Johnson & Johnson ( $JNJ ) memo in court yesterday as attorneys seek to prove the company's Risperdal marketing overstepped its bounds, cheating the state out
Metamark signs potential $365M deal with J&J unit
Metamark Genetics has entered an agreement with Janssen Biotech, a unit of Johnson & Johnson ( $JNJ ), to identify and characterize proprietary cancer targets that play a causal role in promoting
J&J nabs Pharmacyclics cancer candidate in $975M deal
Johnson & Johnson's ( $JNJ ) Janssen Biotech unit has made a big deal with the small biotech Pharmacyclics. Janssen will pay $150 million up front--and $975 million total, if milestones are
